BioMarin Pharmaceutical Inc. (BMRN) Provides Updated Phase 1/2 Data on BMN 673 in Breast Cancer at the European Cancer Congress 2013
9/30/2013 9:08:46 AM
SAN RAFAEL, Calif., Sept. 29, 2013 (GLOBE NEWSWIRE) -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN) today announced an update on the ongoing Phase 1/2 study for its poly ADP-ribose polymerase (PARP) inhibitor, BMN 673, for the treatment of solid tumors. Dr. Ramesh Ramanathan, lead investigator of the study (Medical Director, Virginia G. Piper Cancer Center - Clinical Trials, Scottsdale Health Care, Scottsdale, AZ and Clinical Professor of Medicine, TGEN & College of Medicine, University of Arizona, Phoenix, AZ), presented the data at the Late Breaking Oral Session of the the 17th ECCO – 38th ESMO – 32nd ESTRO European Cancer Congress in Amsterdam, The Netherlands.
Help employers find you! Check out all the jobs and post your resume.
comments powered by